PRELOAD PRELOAD PRELOAD PRELOAD PRELOAD

About Us

Company Overview

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.

The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan ® (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Investigational product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease, sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of PKU.

Company Information

Established: 1997
Headquarters: Novato, California USA
Stock Symbol: NASDAQ: BMRN
Stock Quote: More

2007 Financial Highlights

Total Revenue: $121.6 Million
Net Loss: $15.8 Million
Net Income: $2.6 Million
Employees: 675 worldwide
Clinical Research: Conducted internationally
Products: KUVAN® for PKU, Naglazyme® for MPS VI, Aldurazyme® for MPS I
Commercial Operations: Multinational
Clinical Pipeline: PEG-PAL for PKU, 6R-BH4 for cardiovascular indications, 6R-BH4 for Sickle Cell Disease
Focus: Rare (Orphan) genetic diseases
Strategy: Providing rapid access to treatment for patients with serious unmet medical needs, optimizing powerful biology with demonstrated potential and development clarity, accelerating approval process, strategic pipeline development

Products

BioMarin has developed and commercialized three products in ten years, a remarkable accomplishment in the pharmaceutical industry, and a testament to the company’s passion and dedication to patients with serious unmet medical needs. For complete safety and prescribing information, please visit www.kuvan.com, www.naglazyme.com and www.aldurazyme.com.